Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Inhibition of HIV-1 replication by simian restriction factors, TRIM5α and APOBEC3G

Gene Therapy volume 14, pages 185–189 (2007)Cite this article

Abstract

Old World monkey TRIM5α targets incoming human immunodeficiency virus type 1 (HIV-1) viral capsid, whereas the apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like (APOBEC)3 family hypermutate/degrade viral sequences. Here, we show the potentials of simian TRIM5α and APOBEC3G as therapeutic sequences for AIDS gene therapy. Both rhesus and African green monkey (agm) TRIM5α efficiently restrict HIV-1 vectors with divergent Gag from different HIV-1 subtypes. Human T cells genetically engineered to express agm-TRIM5α block or delay HIV-1 replication. Although agm-APOBEC3G expression alone only transiently suppresses HIV-1 replication, co-expression of agm-APOBEC3G and agm-TRIM5α successfully block the virus replication for more than 5 weeks.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Duan L, Bagasra O, Laughlin MA, Oakes JW, Pomerantz RJ . Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 1994; 91: 5075–5079.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990; 247: 1222–1225.

    Article  CAS  PubMed  Google Scholar 

  3. Ojwang JO, Hampel A, Looney DJ, Wong-Staal F, Rappaport J . Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA 1992; 89: 10802–10806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, Akkina R . Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 2000; 1: 244–254.

    Article  CAS  PubMed  Google Scholar 

  5. Cordelier P, Kulkowsky JW, Ko C, Matskevitch AA, McKee HJ, Rossi JJ et al. Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Therapy 2004; 11: 1627–1637.

    Article  CAS  PubMed  Google Scholar 

  6. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E . Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990; 63: 601–608.

    Article  CAS  PubMed  Google Scholar 

  7. Trono D, Feinberg MB, Baltimore D . HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989; 59: 113–120.

    Article  CAS  PubMed  Google Scholar 

  8. Woffendin C, Ranga U, Yang Z, Xu L, Nabel GJ . Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA 1996; 93: 2889–2894.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 2004; 9: 902–913.

    Article  CAS  PubMed  Google Scholar 

  10. Jacque JM, Triques K, Stevenson M . Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435–438.

    Article  CAS  PubMed  Google Scholar 

  11. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8: 681–686.

    Article  CAS  PubMed  Google Scholar 

  12. Lisziewicz J, Sun D, Klotman M, Agrawal S, Zamecnik P, Gallo R . Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc Natl Acad Sci USA 1992; 89: 11209–11213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002; 20: 500–505.

    Article  CAS  PubMed  Google Scholar 

  14. Qin XF, An DS, Chen IS, Baltimore D . Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183–188.

    Article  CAS  PubMed  Google Scholar 

  15. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78: 2601–2605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sheehy AM, Gaddis NC, Choi JD, Malim MH . Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646–650.

    Article  CAS  PubMed  Google Scholar 

  17. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J . The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427: 848–853.

    Article  CAS  PubMed  Google Scholar 

  18. Sayah DM, Sokolskaja E, Berthoux L, Luban J . Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 2004; 430: 569–573.

    Article  CAS  PubMed  Google Scholar 

  19. Keckesova Z, Ylinen LM, Towers GJ . The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci USA 2004; 101: 10780–10785.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD . Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci USA 2004; 101: 10774–10779.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Yap MW, Nisole S, Lynch C, Stoye JP . Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 2004; 101: 10786–10791.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Simon JH, Malim MH . The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol 1996; 70: 5297–5305.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D . Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424: 99–103.

    Article  CAS  PubMed  Google Scholar 

  24. Ikeda Y, Ylinen LM, Kahar-Bador M, Towers GJ . Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J Virol 2004; 78: 11816–11822.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N et al. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 1992; 66: 7517–7521.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59: 284–291.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, Inoue R et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999; 73: 2343–2349.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Besnier C, Takeuchi Y, Towers G . Restriction of lentivirus in monkeys. Proc Natl Acad Sci USA 2002; 99: 11920–11925.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz PD . Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci USA 2002; 99: 11914–11919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ylinen LM, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ . Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J Virol 2005; 79: 11580–11587.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC . Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005; 435: 108–114.

    Article  CAS  PubMed  Google Scholar 

  32. Anderson J, Akkina R . TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages. Mol Ther 2005; 12: 687–696.

    Article  CAS  PubMed  Google Scholar 

  33. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR . A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 2004; 101: 3770–3774.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Schrofelbauer B, Chen D, Landau NR . A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 2004; 101: 3927–3932.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Stremlau M, Perron M, Welikala S, Sodroski J . Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 2005; 79: 3139–3145.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Sawyer SL, Wu LI, Emerman M, Malik HS . Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci USA 2005; 102: 2832–2837.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Yap MW, Nisole S, Stoye JP . A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 2005; 15: 73–78.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Greg J Towers, University College London for reagents and helpful discussion. The following reagents were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: 174xCEM from Dr Peter Cresswell, GHOST(3)R3/X4/R5 from Dr Vineet N KewalRamani and Dr Dan R Littman, p89.6 from Dr Ronald G Collman, pNL4-3 from Dr Malcolm Martin and pc-AGM-APOBEC3G-HA from Dr Nathaniel Landau. This work was supported by the Mayo Foundation (to YI).

Author information

Authors and Affiliations

  1. Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN, USA

    R Sakuma, J A Noser, S Ohmine & Y Ikeda

Authors
  1. R Sakuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J A Noser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Ohmine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Ikeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sakuma, R., Noser, J., Ohmine, S. et al. Inhibition of HIV-1 replication by simian restriction factors, TRIM5α and APOBEC3G. Gene Ther 14, 185–189 (2007). https://doi.org/10.1038/sj.gt.3302852

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302852

Keywords

This article is cited by

Search

Advanced search

Quick links